Fluvoxamine for stereotypic behavior in patients with dementia

Area of Science:

• Geriatric Psychiatry
• Neuropharmacology
• Movement Disorders

Background:

• Stereotypic movement disorders (SMDs) are common in advanced dementia, significantly impacting patient well-being and care.
• Selective serotonin reuptake inhibitors (SSRIs) are increasingly explored for managing behavioral symptoms in dementia.

Observation:

• This study observed three patients with advanced dementia (Alzheimer's type and vascular dementia) presenting with stereotypic behaviors.
• The patients were treated with fluvoxamine, a selective serotonin reuptake inhibitor, with dosages titrated up to 150 mg/d.

Findings:

• Two out of three patients achieved complete resolution of stereotypic behaviors within six weeks of fluvoxamine treatment.
• The third patient demonstrated notable improvement, though some residual movements persisted after eight weeks.

Implications:

• Fluvoxamine demonstrates potential efficacy in managing stereotypic movement disorders associated with advanced dementia.
• Further research into SSRI use for SMD management in dementia populations is warranted to confirm these findings.